MarginsXMarginsX
Home › Markets › Health Care › VRTX

Vertex Pharmaceuticals Incorporated (VRTX)

VRTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$537.79
-0.15% on the day
Market cap
$136.4B
Large cap
Revenue · 2025
$12.0B
+8.9% on 2024
Net income · 2025
$4.0B
32.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/0000875320-26-000056-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVRTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1991
SEC CIK0000875320
SEC industry codePharmaceutical Preparations
Incorporated inMA

Financials · 2025

LineValue
Revenue$12.0B
Net income$4.0B
Operating income$4.2B
Net margin32.9%
Operating margin34.8%
Revenue growth+8.9%
Cash$5.1B
Total assets$25.6B
P/E (computed)34.5×
P/S (computed)11.4×

Warning signs

Cash runway
Cash-flow positive
$5.0B cash at September 30, 2026
Share count, 1 year
-0.1%
2025-10-31 to 2026-10-31 · -1.6% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$158.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$5.0B cash; operating cash flow $923.6M a quarter.Report 2026-09-30
Shares outstanding253,537,674 (2026-10-31); 253,718,831 a year earlier; 257,683,184 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $158.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3.4B$653.6M$643.1M$5.0B$4.5B$13.0B10-Q 2026-11-03
Q2 2026
2026-06-30
$3.3B$1.1B$1.1B$6.1BNo debt tags$12.6B10-Q 2026-08-04
Q1 2026
2026-03-31
$3.0B$1.0B$1.4B$5.5BNo debt tags$12.2B10-Q 2026-05-05
Q4 2025
2025-12-31
$3.2B$1.2B$498.0M$5.1B$0$12.0B10-K 2026-02-13
Q3 2025
2025-09-30
$3.1B$1.1B$1.2B$4.9BNo debt tags$11.7B10-Q 2026-11-03
Q2 2025
2025-06-30
$3.0B$1.0B$1.1B$5.0BNo debt tags$11.4B10-Q 2026-08-04
Q1 2025
2025-03-31
$2.8B$646.3M$818.9M$4.7BNo debt tags$11.1B10-Q 2026-05-05
Q4 2024
2024-12-31
$2.9B$913.0M$584.6M$4.6BNo debt tags$11.0B10-K 2026-02-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-02-13
Latest annual report10-K2026-02-13
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 1,008 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.6%
1 month+11.0%
3 months+4.3%
Year to date+18.8%
1 year+24.0%
From 52-week high-3.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
SNYSanofi ADS$48.39+0.04%$118.0B
PFEPfizer Inc.$28.86-0.10%$164.5B
GSKGSK plc$50.41-0.08%$102.0B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier